FDA places Arrowhead Hepatitis B drug on partial hold, shares plunge

January 12, 2015 2:11 PM

5 0

(Reuters) - Drug developer Arrowhead Research Corp said the U.S. Food and Drug Administration placed the company's experimental hepatitis B treatment on partial clinical hold, seeking additional data from the drug's mid-stage study.

The company's shares plunged 22 pct premarket on Monday after the FDA also asked the company to reduce the dosage of the drug, ARC-520.

Also read: Celgene quarterly revenue rises 28 percent as Revlimid shines

Read more

To category page